- Home
- LYFT vs IOVA Comparison
LYFT vs IOVA Comparison
Compare LYFT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- IOVA
- Stock Information
- Founded
- LYFT 2007
- IOVA 2007
- Country
- LYFT United States
- IOVA United States
- Employees
- LYFT N/A
- IOVA N/A
- Industry
- LYFT Business Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYFT Consumer Discretionary
- IOVA Health Care
- Exchange
- LYFT Nasdaq
- IOVA Nasdaq
- Market Cap
- LYFT 4.0B
- IOVA 3.6B
- IPO Year
- LYFT 2019
- IOVA N/A
- Fundamental
- Price
- LYFT $11.94
- IOVA $9.29
- Analyst Decision
- LYFT Buy
- IOVA Strong Buy
- Analyst Count
- LYFT 34
- IOVA 10
- Target Price
- LYFT $15.93
- IOVA $24.80
- AVG Volume (30 Days)
- LYFT 11.3M
- IOVA 6.3M
- Earning Date
- LYFT 08-07-2024
- IOVA 11-05-2024
- Dividend Yield
- LYFT N/A
- IOVA N/A
- EPS Growth
- LYFT N/A
- IOVA N/A
- EPS
- LYFT N/A
- IOVA N/A
- Revenue
- LYFT $5,095,182,000.00
- IOVA $32,772,000.00
- Revenue This Year
- LYFT $29.78
- IOVA $13,836.92
- Revenue Next Year
- LYFT $13.26
- IOVA $183.20
- P/E Ratio
- LYFT N/A
- IOVA N/A
- Revenue Growth
- LYFT 19.88
- IOVA 13669.75
- 52 Week Low
- LYFT $8.85
- IOVA $3.21
- 52 Week High
- LYFT $20.82
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- LYFT 55.79
- IOVA 39.99
- Support Level
- LYFT $10.62
- IOVA $8.80
- Resistance Level
- LYFT $11.89
- IOVA $11.80
- Average True Range (ATR)
- LYFT 0.51
- IOVA 0.62
- MACD
- LYFT 0.10
- IOVA -0.33
- Stochastic Oscillator
- LYFT 88.54
- IOVA 12.18
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.